Literature DB >> 3596872

Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.

R Cappelli, S Pecchi, V Oberhauser, S Forconi, T Di Perri.   

Abstract

In a double-blind study the effect of a high dosage of O-(beta-hydroxyethyl)-rutosides (HR) was tested in women taking oral contraceptives and suffering from venous insufficiency of the lower limbs. Ten patients were treated for 28 days with HR (3 g/day) and ten with a placebo. In basal conditions and after therapy, the symptoms of venous disorders and the venous function, by means of strain gauge plethysmography, was evaluated in both groups. The results showed an increase of venous capacitance and a reduction of venous tone in the subjects treated including those without symptoms in the lower limbs. The HR treatment resulted in a significant improvement of the venous function parameters and of the symptoms in lower limbs.

Entities:  

Keywords:  Chronic Diseases; Clinical Research; Contraception; Contraceptive Methods; Developed Countries; Diseases; Drugs; Europe; Examinations And Diagnoses; Family Planning; Human Volunteers; Ingredients And Chemicals; Italy; Laboratory Examinations And Diagnoses; Mediterranean Countries; Oral Contraceptives; Organic Chemicals; Research Methodology; Southern Europe; Treatment; Vascular Diseases; Venous Engorgement

Mesh:

Substances:

Year:  1987        PMID: 3596872

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  2 in total

1.  Double-blind plethysmographic study of venous effects of heptaminol adenosine phosphate in patients with primary varicose veins.

Authors:  C Schmidt; R Gavoille; P Perez; J Schmitt
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Hydroxyethylrutosides. A review of its pharmacology, and therapeutic efficacy in venous insufficiency and related disorders.

Authors:  A N Wadworth; D Faulds
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.